Faculty

Institution

Unit

Venue

Wenli Dong

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Statistical Analysis

The University of Texas MD Anderson Cancer Center

NoneWenli Dong is currently serving as a Statistical Analysis faculty at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Wenli Dong

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

oncology radiation oncology breast cancer cancer care pathology cancer research surgery surgical oncology breast oncology medicine hematology lung cancer thoracic oncology lymphoid neoplasia breast surgery radiation therapy cancer biology clinical research cancer imaging leukemia cancer management cancer treatment hematological malignancies tumor biology outcomes research cancer cells oncogenes clinical radiation oncology contralateral prophylactic mastectomy cancer genetics lymphatic disease respiratory medicine clinical transplantation bone marrow transplantation pain medicine cancer risk cancer screening pancreatic cancer cohort studies oncologic imaging stem cell transplantation myeloid neoplasia cancer discovery diabetes research general surgery neck oncology bronchial neoplasm reconstructive surgery cancer pain immune checkpoint inhibitors survival outcomes prospective study nonhereditary breast cancer early-stage hodgkin lymphoma clinical investigation pharmacotherapy reconstructive microsurgery cancer detection surgical care clinical effectiveness case studies costbenefit analysis prognostic biomarkers neck disorder larynx psychosocial outcomes stereotactic ablative radiotherapy tumor microbiome diversity clinicopathologic features large cohort superovulation strategies functional radiographic markers predicts poor survival metastatic thyroid cancer primary hyperparathyroidism early pathogenesis

Notable Scholarly Works

Notable Federal Grants

Collaborators

1336 Final Ph1B/2 Results for Nous-209 Monotherapy in Lynch Syndrome Carriers: Annual Revaccination Boosts T Cell Immunity Informing Future Cancer Interception Strategies. (2025)

immunologyvaccinesvaccine trialslynch syndrome carriersnous-209 monotherapyradiation oncologyimmune checkpoint inhibitorsnovel therapiesfinal ph1b/2 resultscancer immunotherapyoncologyimmune responsesimmunomodulationcancer letterimmunity (medicine)cellular therapytherapeutic vaccinesimmunotherapy

Abstract 6427: Nous-209 Off-The-Shelf Neoantigen Immunotherapy Induces Robust Neoantigen T Cell Response With the Potential to Intercept Cancer in Lynch Syndrome Carriers. Cancer Research (2025)

Jason WillisAnna Morena D'AliseMichael J. HallMarcia Cruz-CorreaGregory E. IdosSelvi ThirumurthiVeroushka BallesterGuido LeoniIrene GarziaLaura AntonucciLorenzo De MarcoElisa MicarelliSven GogovWenli DongJ. Jack LeeLana A. VornikAraceli Garcia-GonzalezLaura Reyes-UribeEllen RichmondAsad UmarPowel H. BrownLuz Maria RodriguezElisa ScarselliEduardo Vilar

immunologylynch syndrome carrierscancer researchimmune checkpoint inhibitorsnovel therapiescancer immunotherapytherapeutic targetsoncologycancer treatmentcancer biologyspecific resistanceimmunotherapy

Implications of Omitting Sentinel Lymph Node Biopsy on Adjuvant Decision Making for Patients With Small Breast Cancers. Cancer (2025)

medicinebreast surgerymetastasiscancer careradiation oncologysurgical oncologyadjuvant decision makingbreast canceroncologysmall breast cancersbreast oncology

Neoadjuvant Her2-Targeted Regimens With or Without Anthracyclines for Her2-Positive Inflammatory Breast Cancer: A Multicenter Retrospective Study. Breast Cancer Research and Treatment (2025)

immunologypharmacologymolecular cancermulticenter retrospective studycancer immunotherapybreast cancerdrug targetingcancer cellscancer treatmentneoadjuvant her2-targeted regimensbreast oncology

Outcomes of Elderly Patients With Relapsed Refractory Multiple Myeloma (Rrmm) Treated With Teclistamab: A Multicenter Study From the U.S. Multiple Myeloma Immunotherapy Consortium. Blood Cancer Journal (2025)

Oren PasvolskyDanai DimaLei FengWenli DongTiffany RichardsJames A DavisAimaz AfroughMariola Vazquez-MartinezAishwarya SannareddyUtkarsh GoelRahul BanerjeeJack KhouriFrances CervoniMahmoud R GaballaAlex Lieberman-CribbinMasooma Shifa RanaKelley JulianChristopher J FerreriLeyla ShuneShaun DeJarnetteEvguenia BhurtelSandra Susanibar AdaniyaAndrew PortugueseHitomi HosoyaLekha MikkilineniGurbakhash KaurAdriana RossiMegan M HerrDaniel SchrumChenyu LinShahzad RazaYi LinShonali MidhaNadeem OmarShebli AtarshJoseph McGuirkDouglas SborovPeter VoorheesFaiz AnwerMelissa AlsinaCiara FreemanAlfred L GarfallBeatrice M RazzoSurbhi SidanaAndrew J CowanLarry D AndersonDoris K HansenShambavi RichardKrina K PatelHans C LeeAriel Grajales-Cruz

myeloid neoplasiabone marrow transplantationmalignant blood disorderscohort studiesneurologycancer managementcardiologyleukemiasurgical oncologyurologycancer immunotherapylung cancerimmunotherapyimmunologyelderly patientsmulticenter studythoracic oncologyoncologymulti-scale studiesclinical transplantation

Predicting Pathologic ≥N2 Disease in Women With Breast Cancer. npj Breast Cancer (2025)

gynecologic oncologybreast canceroncologycancer riskpathologybreast imagingbreast oncology

Prognostic Impact of Cxcr4 Mutation Type on Clinical Features and Outcomes of Patients With WaldenströM Macroglobulinemia. Blood (2025)

medicinehematologycancer researchclinical featurescxcr4 mutation typeoncologywaldenström macroglobulinemiapathologyhuman geneticsmolecular medicine

Reassessing Estrogen Receptor Expression Thresholds for Breast Cancer Prognosis in Her2-Negative Patients Using Shape Restricted Modeling. Scientific Reports (2025)

endocrine-related cancerssystems biologygynecologic oncologycancer discoverybreast cancer prognosisbiostatisticsbreast cancerher2-negative patientsovarian cancerbreast oncology

Sequence of Therapy Impact on Older Women With Comorbidities and Triple-Negative or Her2-Positive Breast Cancer. npj Breast Cancer (2025)

her2-positive breast cancercancer careolder womencancer managementradiation oncologygynecologic oncologytherapy impactbreast canceroncologygynecologywomen's healthbreast oncology

Ten-Year Outcomes of the Revised Stars Trial Comparing Radiation and Surgery for Early-Stage Non-Small Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics (2025)

surgerybronchial neoplasmoutcomes researchcancer carethoracic oncologyradiation oncologyclinical radiation oncologysurgical oncologymultiple pulmonary nodulethoracic surgeryten-year outcomesclinical trialsoncologyradiation therapylung cancer

1
2
3
4
5
10
10 / page

Wenli Dong

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Statistical Analysis

The University of Texas MD Anderson Cancer Center

NoneWenli Dong is currently serving as a Statistical Analysis faculty at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Wenli Dong

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

1336 Final Ph1B/2 Results for Nous-209 Monotherapy in Lynch Syndrome Carriers: Annual Revaccination Boosts T Cell Immunity Informing Future Cancer Interception Strategies. (2025)

Abstract 6427: Nous-209 Off-The-Shelf Neoantigen Immunotherapy Induces Robust Neoantigen T Cell Response With the Potential to Intercept Cancer in Lynch Syndrome Carriers. Cancer Research (2025)

Implications of Omitting Sentinel Lymph Node Biopsy on Adjuvant Decision Making for Patients With Small Breast Cancers. Cancer (2025)

medicinebreast surgerymetastasiscancer careradiation oncologysurgical oncologyadjuvant decision makingbreast canceroncologysmall breast cancersbreast oncology

Neoadjuvant Her2-Targeted Regimens With or Without Anthracyclines for Her2-Positive Inflammatory Breast Cancer: A Multicenter Retrospective Study. Breast Cancer Research and Treatment (2025)

immunologypharmacologymolecular cancermulticenter retrospective studycancer immunotherapybreast cancerdrug targetingcancer cellscancer treatmentneoadjuvant her2-targeted regimensbreast oncology

Predicting Pathologic ≥N2 Disease in Women With Breast Cancer. npj Breast Cancer (2025)

gynecologic oncologybreast canceroncologycancer riskpathologybreast imagingbreast oncology

Prognostic Impact of Cxcr4 Mutation Type on Clinical Features and Outcomes of Patients With WaldenströM Macroglobulinemia. Blood (2025)

medicinehematologycancer researchclinical featurescxcr4 mutation typeoncologywaldenström macroglobulinemiapathologyhuman geneticsmolecular medicine

Reassessing Estrogen Receptor Expression Thresholds for Breast Cancer Prognosis in Her2-Negative Patients Using Shape Restricted Modeling. Scientific Reports (2025)

endocrine-related cancerssystems biologygynecologic oncologycancer discoverybreast cancer prognosisbiostatisticsbreast cancerher2-negative patientsovarian cancerbreast oncology

Sequence of Therapy Impact on Older Women With Comorbidities and Triple-Negative or Her2-Positive Breast Cancer. npj Breast Cancer (2025)

her2-positive breast cancercancer careolder womencancer managementradiation oncologygynecologic oncologytherapy impactbreast canceroncologygynecologywomen's healthbreast oncology

Ten-Year Outcomes of the Revised Stars Trial Comparing Radiation and Surgery for Early-Stage Non-Small Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics (2025)

1
2
3
4
5
10
10 / page